Generic drug makers are hailing the planned creation of a new government fund designed to support the industry’s manufacturing infrastructure,…
REGULATORY
Astellas’ Xtandi on 2nd Drug List Up for IRA Price Negotiations
The US government has announced a total of 15 drugs up for the second round of Medicare price negotiations under the Inflation Reduction Act (IRA), with Astellas Pharma’s flagship cancer therapy Xtandi (enzalutamide) among them. The US Department of Health…
To read the full story
Related Article
- Astellas Drops IRA Lawsuit after Xtandi Avoids 1st Drug List
September 8, 2023
- First 10 Drugs Named for Medicare Price Negotiations, None from Japan Firms
August 30, 2023
- Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
July 19, 2023
REGULATORY
- Shionogi’s ADHD Game Therapy, CureApp’s Alcoholism App in Line for Approval
February 7, 2025
- Drug Ecosystem Budget Project Is for Private Sector: Minister
February 7, 2025
- Japan’s 1st Hemophilia B Gene Therapy Up for Panel Review on Feb. 19
February 6, 2025
- PMD Act Set for Amendments Covering Issues Unaddressed over Past Decade: MHLW Official
February 4, 2025
- Council OKs Public Knowledge Application for CellCept Label Expansion
February 3, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…